

May 11, 2015

As of May 8, Novozymes has purchased an accumulated 2,127,736 shares with a transaction value of DKK 678.5 million under the stock buyback program Novozymes announced in Company announcement No. 6, 2015 and initiated February 2, 2015. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2015.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,983,921		633,932,274
4 May 2015	22,410	310.82	6,965,406
5 May 2015	21,405	316.15	6,767,260
6 May 2015	70,000	308.54	21,597,696
7 May 2015	10,000	304.05	3,040,457
8 May 2015	20,000	310.35	6,207,033
Accumulated under the program	2,127,736		678,510,126

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 9,660 B shares in the period from May 4 to May 8, 2015. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 6,046,563 treasury shares, corresponding to 1.9% of the stock capital. The total number of shares in the company is 313,000,000, including treasury shares.

## Contact information

Investor	Relations:
IIIVCStOI	riciations.

Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping to build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

NASDAQ OMX: NZYM-B • 6,500 employees • 12B DDK turnover • 30+ industries • 700+ products

Investor Relations CVR number: 10 00 71 27 Page 1 of 1

Telephone: +45 4446 0000 Email: novozymesIR@novozymes.com Internet: www.novozymes.com